Drug Profile
HIV T-cell therapy - TC Biopharm
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator TC BioPharm
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in HIV-infections in United Kingdom (Parenteral)
- 07 Jan 2015 Early research in HIV infections in United Kingdom (Parenteral)